Improved Targeting of Cancers with Nanotherapeutics.
Targeted cancer nanotherapeutics offers numerous opportunities for the selective uptake of toxic chemotherapies within tumors and cancer cells. The unique properties of nanoparticles, such as their small size, large surface-to-volume ratios, and the ability to achieve multivalency of targeting ligands on their surface, provide superior advantages for nanoparticle-based drug delivery to a variety of cancers. This review highlights various key concepts in the design of targeted nanotherapeutics for cancer therapy, and discusses physicochemical parameters affecting nanoparticle targeting, along with recent developments for cancer-targeted nanomedicines.
Ligandal Inc., Berkeley, CA, 94710, USA.
Christian
C
Foster
Ligandal Inc., Berkeley, CA, 94710, USA.
Andre
A
Watson
Department of Micro and Nanotechnology, DTU Nanotech, Technical University of Denmark, Produktionstorvet, 2800, Kongens Lyngby, Denmark.
Joseph
J
Kaplinsky
Department of Micro and Nanotechnology, DTU Nanotech, Technical University of Denmark, Produktionstorvet, 2800, Kongens Lyngby, Denmark. nazk@nanotech.dtu.dk.
Nazila
N
Kamaly
D000970:Antineoplastic Agents / Q000008:administration & dosage; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D006801:Humans; D058990:Molecular Targeted Therapy; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013499:Surface Properties; D059016:Tumor Microenvironment
D000970:Antineoplastic Agents; D004337:Drug Carriers
Antibodies; Cancer; Drug delivery; EPR; Ligands; Multivalency; Nanomedicine; Nanoparticles; Nanotherapeutics; Oncology; Targeting; Translation